METABOLIC & WEIGHT RESEARCH / FAQ
Questions From the Literature
Direct, citation-grounded answers to the questions most often asked about retatrutide and tirzepatide.
What does retatrutide do?
Retatrutide is an investigational peptide that activates three receptors simultaneously: GIP, GLP-1 and glucagon. The GLP-1 and GIP arms suppress appetite and augment insulin secretion in a glucose-dependent manner; the glucagon arm increases energy expenditure and lipid oxidation [1][4]. In Phase 2 trials the combined effect produced mean body-weight reductions of up to −24.2% at the highest dose over 48 weeks in adults with obesity, and −16.94% in adults with type 2 diabetes over 36 weeks [4][5]. It has not been approved by any regulator; all figures are from Phase 2 trials.
How does retatrutide work?
Retatrutide is acylated with a fatty-diacid group that binds to plasma albumin, extending its half-life to approximately 6 days and enabling once-weekly subcutaneous dosing [6]. At the molecular level, cryo-EM structures confirm that it engages GLP-1R, GIPR, and GCGR simultaneously as a single molecule [2]. The glucagon receptor component is attenuated (approximately 0.3× native glucagon) to limit unwanted hepatic glucose output while preserving thermogenic energy expenditure — the increment over dual agonists [2].
How is retatrutide reconstituted?
This desk does not describe reconstitution, preparation, or administration of retatrutide. The compound is investigational and not approved; any handling procedures described on this site could constitute implicit guidance on human use, which this desk explicitly does not provide. Retatrutide in Phase 3 trials is administered under clinical supervision [1][4]. Any material sold outside a clinical trial is unregulated; this desk makes no recommendation about it.
Is retatrutide FDA approved?
No. As of mid-2026, retatrutide is not approved by the FDA or any regulatory agency. It remains in Phase 3 clinical trials under the TRIUMPH program. Eli Lilly is the sponsor. All existing efficacy and safety figures come from Phase 1 and Phase 2 trial data [1][4][5][6]. Phase 3 results are not yet available.
What is tirzepatide?
Tirzepatide is an FDA-approved synthetic peptide that activates both the GIP and GLP-1 receptors — the first approved twincretin. It was first approved in May 2022 for type 2 diabetes mellitus, and subsequently for chronic weight management in adults with obesity or overweight plus a weight-related condition, and for moderate-to-severe obstructive sleep apnea [9]. All approved formulations are prescription medicines; this desk uses only the international nonproprietary name.
How does tirzepatide work?
Tirzepatide is a 39-amino-acid peptide acylated for albumin binding and an approximately 5-day half-life, enabling once-weekly dosing. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and boosts glucose-dependent insulin secretion. GIP receptor activation further potentiates insulin secretion and modulates lipid metabolism in adipose tissue [9]. Engaging both receptors produces greater glucose-lowering and weight reduction than selective GLP-1 agonism alone — a difference confirmed in head-to-head trial data [12][8].
What does tirzepatide do in the body?
In clinical trials, tirzepatide reduced HbA1c, body weight, waist circumference, and triglycerides; it also improved measures in obstructive sleep apnea. SURMOUNT-1 (72 weeks, 2,539 participants) showed mean weight reductions of up to −20.9% at 15 mg versus −3.1% for placebo [11]. SURMOUNT-5 showed tirzepatide superior to the maximum tolerated dose of another approved incretin at 72 weeks, with mean weight loss of −20.2% versus −13.7% [8]. GI adverse events — nausea, diarrhea, constipation — are the most common side effects and are dose-dependent, mostly emerging during escalation [9][10].
What is tirzepatide used for?
Tirzepatide is approved for: (1) type 2 diabetes mellitus in adults; (2) chronic weight management in adults with initial BMI ≥30, or ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea); and (3) moderate-to-severe obstructive sleep apnea in adults with obesity [9]. Weight-related comorbidity improvement — glycemic control, lipid profiles, blood pressure — is extensively documented in the trial programs [11][12]. It is a prescription-only medicine.
Is tirzepatide the same as retatrutide?
No. Both are acylated 39-amino-acid incretin peptides, but tirzepatide is a dual GIP/GLP-1 receptor agonist and retatrutide is a triple GIP/GLP-1/glucagon receptor agonist. Tirzepatide is FDA-approved; retatrutide is investigational [1][9]. The glucagon receptor arm in retatrutide adds energy expenditure and lipid oxidation that tirzepatide does not carry [2][4]. They have different molecular structures, different relative receptor potencies, and different regulatory statuses.
What is the difference in weight loss between retatrutide and tirzepatide?
Across available Phase 2 trial data, retatrutide 12 mg produced a mean −24.2% body-weight change at 48 weeks in adults with obesity [4]. Tirzepatide 15 mg produced a mean −20.9% body-weight change at 72 weeks in SURMOUNT-1 [11]. These figures come from different trials with different populations, durations, and enrollment criteria and cannot be directly compared; head-to-head data between these two specific compounds do not yet exist. Phase 3 data from the TRIUMPH program will provide the next major calibration [1].
Are these peptides safe?
Tirzepatide has a well-characterized safety profile across completed Phase 3 trials. Its primary adverse effects are GI (dose-dependent nausea, diarrhea, constipation); a statistically significant increase in gallbladder or biliary disease has been found in meta-analyses (RR 1.97); the label carries a boxed warning about thyroid C-cell tumours based on rodent data [9][10]. Long-term cardiovascular outcomes in obesity are being studied. Retatrutide's safety profile is still being defined in Phase 3; GI adverse events and heart-rate elevation were the primary signals in Phase 2 [4][5]. Neither compound has an established long-term safety record in unmonitored settings outside clinical trials.
What does this site not tell me?
This desk does not tell a reader what dose to use, whether to obtain either compound outside of a clinical trial, or whether either compound is appropriate for any individual's circumstances. It does not diagnose any condition, recommend any supplier, or advise on reconstitution, administration schedule, or any other practical use question. These are published research summaries, not clinical guidance. For questions relevant to a personal health situation, a licensed clinician in the appropriate jurisdiction is the appropriate source.